

Corp. Office : 2nd & 3rd Floor, Old Sanskar Jyot School Bldg., (Above Bank of Maharashtra), S. V. Road, Andheri (West), Mumbai - 400 058.
Tel. 022-6726 1000 Fax : (91-22) 6726 1067 Email : Gufic@guficbio.com

Ref No : 04/JAN/SE/ 2018/GBSL

January 22 , 2018

To
The Manager
National Stock Exchange Of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Symbol : GUFICBIO

Dear Sirs,

Re : Your email dated January 8, 2018 with respect to Clarification for Financial results
- GUFICBIO


Sub.: Reply to the Clarification sought

With respect to the above stated reference, kindly find the segment results along with the details of segment assets and liabilities for the quarter and half year ended September 30, 2017


You are requested to take the same on record.

Thanking you,

For Gufic Biosciences Limited



Ami Shah
Company Secretary & Compliance Officer
Membership No. A39579



GUFIC BIOSCIENCES LIMITED

CIN:L65990MH1984PLC033519

Regd. Office:37, First Floor, Kamala Bhavan II, S. Nityanad Road, Andheri (East), Mumbai 400 069.

Tel No. 022-6726 1000 Fax. No. 022 6726 1068

Email id:info@guficbio.com, website:www.gufic.com

Segmentwise Revenue, Results and Capital Employed for the Quarter Ended September 30, 2017

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended			Half Year Ended	
		30-Sep-17	30-Jun-17	30-Sep-16	30-Sep-17	30-Sep-16
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
1	SEGMENT REVENUE					
	Sales & Service					
	Pharma	7061.9	5291.92	6134.29	12357.87	11644.44
	Consumer	-	-	294.96	-	321.06
	Bulk Drug	423.05	1,046.44	-	1,469.48	-
	Total	7,484.95	6,338.36	6,429.25	13,827.35	11,965.50
	Unallocable Income	84.83	11.84	15.50	92.63	30.57
	Total Segment Revenue	7,569.78	6,350.20	6,444.75	13,919.98	11,996.07
2	SEGMENT RESULTS					
	Pharma	1341.761	899.63	1488.71	2348.00	2740.86
	Consumer	0	-	30.39	0	32.77
	Bulk Drug	76.15	198.82	-	264.51	-
	Unallocabel Income	51.38	107.49	-	158.87	-
	Total	1,469.29	1,205.94	1,519.10	2,771.37	2,773.63
	Less: Unallocated over heads	357.01	33.61	837.09	486.75	1448.55
	Finance Charges	269.21	175.53	141.41	444.74	278.32
	Excise Charges	0	315.52	0	315.52	0
	Depreciation	97.67	93.29	93.68	190.96	184.8
	Tax provision	178.71	233.87	183.21	412.58	343
	Net Profit After Tax	566.69	354.12	263.21	920.81	518.96
3	Capital Employed					
	(Segment Asset - Segment Liabilities)					
	SEGMENTS ASSESTS					
	Pharma	20,184.21	17,412.30	15,621.43	20,184.21	15,621.43
	Consumer	-	-	672.92	-	672.92
	Bulk Drug	2,647.06	3,550.09	1,564.58	2,647.06	1,564.58
	Total	22,831.27	20,962.39	17,858.93	22,831.27	17,858.93
	SEGMENTS LIABLITIES					
	Pharma	14,483.91	12,447.75	11,715.90	14,483.91	11,715.90
	Consumer	-	-	532.54	-	532.54
	Bulk Drug	2,452.41	3,028.52	840.40	2,452.41	840.40
	Total	16,936.32	15,476.27	13,088.84	16,936.32	13,088.84
	Total Capital Employed	5,894.95	5,486.12	4,770.09	5,894.95	4,770.09
	Place : Mumbai Date: 14/12/2017 For Gufic Biosciences Ltd  Hemal M. Desai CFO & Whole Time Director DIN - 07014744 